7 Most Promising Biotech Stocks to Buy According to Hedge Funds

4. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Number of Hedge Fund Holdings: 60

According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns 1,163,755 shares of the company’s stock, reflecting an investment worth $42,314,000 and ownership of about 1.23%.

During the latest earnings call, management highlighted the company’s history of accelerating programs through approval in several areas. While reporting Breakthrough Therapy designation for GTX-102 in Angelman syndrome, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appears to be in a good position to advance UX143, which will be a transformational treatment for pediatric and adult patients with osteogenesis imperfecta.

 On September 26, 2025, Regeneron Pharmaceuticals announced the FDA approval of a label expansion for its anti-cholesterol agent Evkeeza, which is offered globally, in collaboration with Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). This, along with other strategic collaborations, hints at a positive outlook for the company.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a California-based biopharmaceutical company that discovers, develops, and commercializes novel products for treating rare and ultra-rare genetic diseases. The core offerings of the company include Crysvita (burosumab), Mepsevii, Dojolvi, and Evkeeza (evinacumab).